Targeting EZH1/2: tackling epigenetic resistance advances cancer therapy
2025
Targeting EZH1/2 in Cancer Therapy
Sample size: 1000
publication
Evidence: moderate
Author Information
Author(s): Zaki Ram Abou, El‐Osta Assam
Primary Institution: Baker Heart and Diabetes Institute
Hypothesis
Can targeting EZH1/2 improve cancer therapy outcomes?
Conclusion
The study found that valemetostat treatment can lead to tumor regression in ATL patients by reducing histone methylation and activating tumor suppressor genes.
Supporting Evidence
- Valemetostat treatment showed tumor regression as early as the first week.
- Almost 50% of ATL patients acquired mutations affecting drug response.
- Combination therapy with decitabine restored valemetostat efficacy.
Takeaway
This study shows that a new drug can help shrink tumors in a rare type of blood cancer by changing how genes are turned on and off.
Methodology
The study involved Phase I and II trials assessing the effects of valemetostat on ATL patients.
Limitations
The study findings are preliminary and variability in patient response was noted.
Participant Demographics
Patients with adult T-cell leukemia/lymphoma, primarily diagnosed in Japan.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website